EE200200031A - 1,4,5,6-tetrahüdropürimidiini derivaat, selle valmistamismeetod, farmatseutiline kompositsioon, vaheühend ja selle valmistamismeetod - Google Patents

1,4,5,6-tetrahüdropürimidiini derivaat, selle valmistamismeetod, farmatseutiline kompositsioon, vaheühend ja selle valmistamismeetod

Info

Publication number
EE200200031A
EE200200031A EEP200200031A EEP200200031A EE200200031A EE 200200031 A EE200200031 A EE 200200031A EE P200200031 A EEP200200031 A EE P200200031A EE P200200031 A EEP200200031 A EE P200200031A EE 200200031 A EE200200031 A EE 200200031A
Authority
EE
Estonia
Prior art keywords
preparation
pharmaceutical composition
tetrahydropyrimidine derivative
tetrahydropyrimidine
derivative
Prior art date
Application number
EEP200200031A
Other languages
English (en)
Estonian (et)
Inventor
Breipohl Gerhard
Peyman Anuschirwan
Wollmann Theodor
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of EE200200031A publication Critical patent/EE200200031A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200200031A 1999-07-21 2000-07-08 1,4,5,6-tetrahüdropürimidiini derivaat, selle valmistamismeetod, farmatseutiline kompositsioon, vaheühend ja selle valmistamismeetod EE200200031A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99114372A EP1070707A1 (en) 1999-07-21 1999-07-21 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor
PCT/EP2000/006504 WO2001007417A1 (en) 1999-07-21 2000-07-08 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor

Publications (1)

Publication Number Publication Date
EE200200031A true EE200200031A (et) 2003-02-17

Family

ID=8238643

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200031A EE200200031A (et) 1999-07-21 2000-07-08 1,4,5,6-tetrahüdropürimidiini derivaat, selle valmistamismeetod, farmatseutiline kompositsioon, vaheühend ja selle valmistamismeetod

Country Status (29)

Country Link
US (1) US6900318B1 (pl)
EP (2) EP1070707A1 (pl)
JP (1) JP2003505450A (pl)
KR (1) KR20020063838A (pl)
CN (1) CN1361767A (pl)
AR (1) AR024794A1 (pl)
AT (1) ATE286030T1 (pl)
AU (1) AU775567B2 (pl)
BG (1) BG106322A (pl)
BR (1) BR0012554A (pl)
CA (1) CA2379086C (pl)
CZ (1) CZ200285A3 (pl)
DE (1) DE60017150D1 (pl)
EA (1) EA200200187A1 (pl)
EE (1) EE200200031A (pl)
HK (1) HK1048316A1 (pl)
HR (1) HRP20020057A2 (pl)
HU (1) HUP0201939A3 (pl)
IL (1) IL147396A0 (pl)
MX (1) MXPA02000674A (pl)
MY (1) MY133525A (pl)
NO (1) NO20020311D0 (pl)
NZ (1) NZ516233A (pl)
PL (1) PL353014A1 (pl)
SK (1) SK522002A3 (pl)
TR (1) TR200200116T2 (pl)
WO (1) WO2001007417A1 (pl)
YU (1) YU90201A (pl)
ZA (1) ZA200110361B (pl)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE227567T1 (de) * 1994-05-27 2002-11-15 Merck & Co Inc Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
BR9907735A (pt) * 1998-01-23 2000-10-17 Aventis Pharma Gmbh Derivados de sulfonamida como inibidores da reabsorção óssea e como inibidores da aderência celular
US6313119B1 (en) * 1998-01-23 2001-11-06 Adventis Pharma Deutschland Gmbh Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion

Also Published As

Publication number Publication date
US6900318B1 (en) 2005-05-31
YU90201A (sh) 2004-07-15
EP1204646A1 (en) 2002-05-15
MY133525A (en) 2007-11-30
AU775567B2 (en) 2004-08-05
CA2379086A1 (en) 2001-02-01
ATE286030T1 (de) 2005-01-15
AR024794A1 (es) 2002-10-23
CZ200285A3 (cs) 2003-02-12
NO20020311L (no) 2002-01-21
IL147396A0 (en) 2002-08-14
HUP0201939A2 (hu) 2002-12-28
EP1070707A1 (en) 2001-01-24
HK1048316A1 (zh) 2003-03-28
CN1361767A (zh) 2002-07-31
AU6822600A (en) 2001-02-13
SK522002A3 (en) 2003-05-02
WO2001007417A1 (en) 2001-02-01
CA2379086C (en) 2009-01-06
NZ516233A (en) 2004-07-30
EP1204646B1 (en) 2004-12-29
NO20020311D0 (no) 2002-01-21
HRP20020057A2 (en) 2003-06-30
JP2003505450A (ja) 2003-02-12
ZA200110361B (en) 2002-12-18
TR200200116T2 (tr) 2002-04-22
DE60017150D1 (de) 2005-02-03
HUP0201939A3 (en) 2003-02-28
MXPA02000674A (es) 2002-07-30
EA200200187A1 (ru) 2002-10-31
BG106322A (en) 2002-08-30
PL353014A1 (pl) 2003-10-06
BR0012554A (pt) 2002-04-16
KR20020063838A (ko) 2002-08-05

Similar Documents

Publication Publication Date Title
EE05214B1 (et) Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
EE200100684A (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE200100252A (et) Pürimidiinderivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja sellevalmistamismeetod, kombinatsioon ning saadus
EE04739B1 (et) Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ning vaheühend ja selle valmistamismeetod
EE200200487A (et) Asetidiini derivaadid, nende valmistamismeetodid ja farmatseutiline kompositsioon
EE200200095A (et) Sulfonüülkarboksamiidi derivaadid, nende kasutamine, ravim ja nende valmistamismeetod
EE200100431A (et) 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
EE200000613A (et) Kinoliini derivaadid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
EE200100594A (et) Uudsed ravimikompositsioonid, mis põhinevad antikolinergiliselt toimivatel ühenditel ja ß-mimeetikumidel
EE200300236A (et) 1,2-difenüülasetidinoonid, nende kasutamine, ravim ja selle valmistamismeetod
EE200200486A (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, uued derivaadid ja nende valmistamismeetodid
EE200100318A (et) Kinoliini derivaat, selle ühendi kasutamine ravimina, seda sisaldav farmatseutiline kompositsioon ning meetod ühendi ja kompositsiooni valmistamiseks
EE200200017A (et) Kinuklidiinderivaadid, nende valmistamismeetod, vaheühendid, farmatseutiline kompositsioon ja nendekasutamine
NO20015175D0 (no) Farmasöytisk sammensetning
NO20016038L (no) Benzenderivater, fremgangsmåte for deres fremstilling og farmasöytiske preparater inneholdende de samme
EE03338B1 (et) Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
EE200200298A (et) Asendatud ftalotsüaniinid ja nende lähteühendid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja materjal
AU2003289641A1 (en) The novel coumarin-amide derivatives and its preparation, said drug composition and its use
EE200000767A (et) Asendatud triasolopüridasiini derivaat, selle valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon
EE9900112A (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE04346B1 (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE03691B1 (et) 1,2,3,4-tetrahüdrobensofuro[3,4-c]püridiini derivaadid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE04902B1 (et) Mikrograanul, selle valmistamismeetod ja farmatseutiline preparaat
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
EE200100209A (et) Tritsüklilised 3-piperidiinid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod